scispace - formally typeset
J

James A. Bonner

Researcher at University of Alabama at Birmingham

Publications -  252
Citations -  17463

James A. Bonner is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Radiation therapy & Cetuximab. The author has an hindex of 56, co-authored 237 publications receiving 16175 citations. Previous affiliations of James A. Bonner include University of Alabama & University of Michigan.

Papers
More filters
Journal ArticleDOI

Current guidelines for the management of small cell lung cancer.

TL;DR: Combined modality approaches, such as radiotherapy administered concomitantly with the initiation of chemotherapy, induction chemotherapy followed by radiotherapy administer during the subsequent courses of chemotherapy), sequential chemotherapy and radiotherapy, and courses of radiotherapy split between cycles of chemotherapy are important for improving survival in patients with SCLC.
Journal ArticleDOI

Bronchial carcinoid tumors: importance of prognostic factors that influence patterns of recurrence and overall survival.

TL;DR: Atypical histologic findings in patients who had undergone complete resection of bronchial carcinoid tumors were associated with increased local-regional disease recurrence and decreased survival compared with recurrences and survival in patients with typical Histologic findings.
Journal ArticleDOI

Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma.

TL;DR: These studies revealed that the greater anti-proliferative effects and increased cytotoxicity of cetuximab in the STAT3-2.17 cells, may be a result ofSTAT3-mediated effects on cellular apoptosis and DNA damage.
Journal ArticleDOI

Epidermal growth factor receptor as a therapeutic target in head and neck cancer

TL;DR: Patients with head and neck carcinomas are being evaluated in phase III studies exploring the combination of IMC-C225 and radiation as well as the combination with radiotherapy or chemotherapy and cisplatin in locally advanced and recurrent disease.
Journal ArticleDOI

MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma.

TL;DR: Patients with high MARCKS expressing tumors of the proneural molecular subtype of GBM had significantly increased survival rates, and this effect was most pronounced in tumors with unmethylated O6-methylguanine DNA methyltransferase (MGMT) promoters, a traditionally poor prognostic factor.